| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
Febuxostat impurity 7 is an impurity of febuxostat and does not have a defined pharmacological target. Febuxostat itself targets xanthine oxidase (XO). The impurity is used as a reference standard for quality control.
|
|---|---|
| ln Vitro |
Febuxostat impurity 7 does not exhibit significant pharmacological activity. It is a chemical impurity of febuxostat. Its primary use is as a reference standard for the identification and quantification of impurities in febuxostat formulations by HPLC.
|
| ln Vivo |
In vivo, Febuxostat impurity 7 is not administered as a therapeutic agent. It may be present as a trace impurity in febuxostat formulations. Its safety and toxicological profile are assessed in the context of pharmaceutical quality control to ensure that impurity levels remain below acceptable limits.
|
| Enzyme Assay |
In vitro assays for Febuxostat impurity 7 typically involve its use as a reference standard in HPLC or LC-MS methods for impurity profiling of febuxostat. The compound is characterized by its retention time, UV spectrum, and mass spectrum. System suitability tests are performed to ensure proper separation from febuxostat and other impurities.
|
| Cell Assay |
For in vitro cell assays, Febuxostat impurity 7 is not typically used as a treatment. It may be tested for cytotoxicity in cell-based assays to assess its safety as an impurity. Cells are cultured and treated with the compound at various concentrations, and cell viability is assessed by standard assays. Results are used to establish acceptable impurity limits.
|
| Animal Protocol |
For in vivo animal studies, Febuxostat impurity 7 is not typically administered as a therapeutic agent. Toxicological studies may be conducted to assess the safety of this impurity at relevant exposure levels. Animals are administered febuxostat formulations containing the impurity, and toxicological endpoints are monitored.
|
| ADME/Pharmacokinetics |
Febuxostat impurity 7 (MW 334.39) has the molecular formula C₁₆H₁₈N₂O₄S. The compound is stable under recommended storage conditions. It is a process-related byproduct formed during the synthesis of febuxostat.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a pharmaceutical impurity, its toxicity is assessed in the context of quality control to ensure patient safety. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Manne Satyanarayana Reddy, et al. Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts. WO2011141933A2.
|
| Additional Infomation |
Febuxostat impurity 7 (CAS# 1350352-70-3) is a designated impurity of the xanthine oxidase inhibitor febuxostat. It has not been approved as a therapeutic agent. The compound is used as a reference standard in pharmaceutical quality control for impurity profiling of febuxostat formulations. It is also known as Febuxostat impurity 7.
|
| Molecular Formula |
C16H18N2O4S
|
|---|---|
| Molecular Weight |
334.39
|
| Exact Mass |
334.099
|
| CAS # |
1350352-70-3
|
| PubChem CID |
54588800
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.659
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(C(O)=O)=C(C)N=C1C1=CC=C(OCC(C)C)C(/C=N/O)=C1
|
| InChi Key |
MDMGIABSBHFMNF-REZTVBANSA-N
|
| InChi Code |
InChI=1S/C16H18N2O4S/c1-9(2)8-22-13-5-4-11(6-12(13)7-17-21)15-18-10(3)14(23-15)16(19)20/h4-7,9,21H,8H2,1-3H3,(H,19,20)/b17-7+
|
| Chemical Name |
2-[3-[(E)-hydroxyiminomethyl]-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (747.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9905 mL | 14.9526 mL | 29.9052 mL | |
| 5 mM | 0.5981 mL | 2.9905 mL | 5.9810 mL | |
| 10 mM | 0.2991 mL | 1.4953 mL | 2.9905 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
